HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Prevalence of non-alcoholic steatohepatitis in morbidly obese subjects undergoing gastric bypass.

AbstractBACKGROUND:
Obesity is the most common cause of non-alcoholic steatohepatitis (NASH). This is a prospective study to determine the incidence and severity of NASH in patients undergoing Roux-en-Y gastric bypass (RYGBP) for morbid obesity. We also examined the relationship between NASH and potential risk factors.
METHODS:
In 48 consecutive patients at RYGBP, a core liver biopsy was obtained from the left lateral segment. A single liver pathologist reviewed the histology for steatosis, ballooning/disarray, necroinflammation, and fibrosis.
RESULTS:
84% of patients were female, and average BMI was 51. 18% had WHR >1. The following risk factors were present: DM 16%; hyperlipidemia 61%; HTN 47%; and abnormal LFTs 18%. 90% had abnormal liver histology, and 56% qualified for the diagnosis of NASH. Only DM and abnormal LFTs were found to be significantly related to NASH.
CONCLUSIONS:
NASH is a common co-morbidity of obesity and requires systemized grading and staging to develop accurate knowledge of the incidence, severity, natural history and impact of weight loss.
AuthorsLaurie Spaulding, Thomas Trainer, Dorota Janiec
JournalObesity surgery (Obes Surg) Vol. 13 Issue 3 Pg. 347-9 (Jun 2003) ISSN: 0960-8923 [Print] United States
PMID12841891 (Publication Type: Comparative Study, Journal Article)
Topics
  • Age Distribution
  • Anastomosis, Roux-en-Y
  • Biopsy, Needle
  • Comorbidity
  • Fatty Liver (epidemiology, pathology)
  • Female
  • Follow-Up Studies
  • Gastric Bypass (methods)
  • Humans
  • Immunohistochemistry
  • Male
  • Obesity, Morbid (epidemiology, surgery)
  • Prevalence
  • Prospective Studies
  • Risk Assessment
  • Sampling Studies
  • Severity of Illness Index
  • Sex Distribution

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: